CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-908-5179500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
When did CorMedix's stock split? How did CorMedix's stock split work?
CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) released its quarterly earnings data on Tuesday, August, 13th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The biotechnology company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.13 million. View CorMedix's Earnings History.
When is CorMedix's next earnings date?
What price target have analysts set for CRMD?
2 analysts have issued twelve-month target prices for CorMedix's stock. Their forecasts range from $14.00 to $30.00. On average, they expect CorMedix's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price. View Analyst Price Targets for CorMedix.
What is the consensus analysts' recommendation for CorMedix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.
What are Wall Street analysts saying about CorMedix stock?
Here are some recent quotes from research analysts about CorMedix stock:
- 1. According to Zacks Investment Research, "CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey. " (8/21/2019)
- 2. HC Wainwright analysts commented, "We derive a value of $470M for Neutrolin using a 12% discount rate and 90% probability of success, along with a 23% effective tax rate, or a price per share of $3.50, taking into account $150M from additional value drivers (ex-U.S. sales, taurolidine gel formulation, and future medical device applications)—up from the prior $120M—and ~141M fully-diluted shares outstanding—including issuance of about 35M more shares due to warrant exercises and further stock issuances—as of end-2019. Our valuation of Neutrolin has risen to $350M from the previous $300M, based on higher peak sales potential." (1/18/2019)
Has CorMedix been receiving favorable news coverage?
Press coverage about CRMD stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CorMedix earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for CorMedix.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include Mesoblast (MSB), Resverlogix (RVX), Neptune Wellness Solutions (NEPT), Oxford BioMedica (OXB), Starpharma (SPL), BELLUS Health (BLU), Kodiak Sciences (KOD), Biotest (BIO), Theratechnologies (TH), Rafael (RFL), Emerald Health Therapeutics (EMH), CEL-SCI (CVM), ProMetic Life Sciences (PLI), Paradigm Biopharmaceuticals (PAR) and Emblem (EMC).
What other stocks do shareholders of CorMedix own?
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 61)
- Mr. Robert W. Cook, Chief Financial Officer (Age 63)
- Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)
- Dr. Phoebe Mounts, Exec. VP & Gen. Counsel
Who are CorMedix's major shareholders?
CorMedix's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.87%), Vanguard Group Inc. (4.34%), Cresset Asset Management LLC (1.38%), Northern Trust Corp (0.43%), Bank of New York Mellon Corp (0.33%) and Steward Partners Investment Advisory LLC (0.27%). Company insiders that own CorMedix stock include Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.
Which major investors are selling CorMedix stock?
Which major investors are buying CorMedix stock?
CRMD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Cresset Asset Management LLC, Vanguard Group Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, Steward Partners Investment Advisory LLC and CIBC Private Wealth Group LLC. Company insiders that have bought CorMedix stock in the last two years include Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.
How do I buy shares of CorMedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $8.04.
How big of a company is CorMedix?
What is CorMedix's official website?
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
